Study shows opioid use among US patients with knee osteoarthritis costs 14 billion dollars in societal costs
Although guidelines do not recommend use of opioids to manage pain for individuals with knee osteoarthritis, a recent study published early online in Arthritis Care & Research, an official journal of the American College of Rheumatology and the Association of Rheumatology Professionals, estimates that 858,000 Americans use opioids such as tramadol and oxycodone for their knee pain, equating to $14 billion in lifetime opioid-related societal costs, or nearly $0.5 billion annually.
Surgeons who participate in the American Joint Replacement Register (AJRR) have contributed the details on nearly 1 million primary total knee arthroplasties (TKA) performed in the US, providing a snapshot of trends in this common orthopaedic procedure.
This year, COVID-19 has made decisions around surgery tougher than ever for folks who may need one. But one major medical group can help provide some answers.
When a person experiences pain in the back of their knee when straightening their leg, it is called posterior knee pain. Pain in the back of the knee, called the popliteal fossa, is common, but there is a wide range of causes, ranging from ligament injury to arthritis.
A review of literature providing insights into one of the head-sparing surgical treatments for this multifactorial disease process: core decompression with the addition of bone marrow aspirate concentrate, which has significantly improved long-term outcomes and has become a powerful tool in treating early-stage osteonecrosis of the femoral head.